Gastroenterology
Volume 138, Issue 4 , Pages 1286-1296.e3 , April 2010

Once-Daily Dosing of Delayed-Release Oral Mesalamine (400-mg Tablet) Is as Effective as Twice-Daily Dosing for Maintenance of Remission of Ulcerative Colitis

  • William J. Sandborn

      Affiliations

    • Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota
    • Corresponding Author InformationReprint requests Address requests for reprints to: William J. Sandborn, MD, Inflammatory Bowel Disease Clinic, Division of Gastroenterology and Hepatology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905. fax: (507) 266-0335
    • ,
  • Joshua Korzenik

      Affiliations

    • Crohn's & Colitis Center and Gastrointestinal Unit, Massachusetts General Hospital, Boston, Massachusetts
    • ,
  • Bret Lashner

      Affiliations

    • Digestive Disease Institute, Cleveland Clinic, Cleveland, Ohio
    • ,
  • Jonathan A. Leighton

      Affiliations

    • Division of Gastroenterology and Hepatology, Mayo Clinic Arizona, Scottsdale, Arizona
    • ,
  • Uma Mahadevan

      Affiliations

    • Center for Colitis and Crohn's Disease, University of California, San Francisco, California
    • ,
  • James F. Marion

      Affiliations

    • Department of Medicine, Division of Gastroenterology, Mt. Sinai School of Medicine, New York, New York
    • ,
  • Michael Safdi

      Affiliations

    • Ohio Gastroenterology and Liver Institute, Cincinnati, Ohio
    • ,
  • Charles A. Sninsky

      Affiliations

    • Digestive Disease Associates, Gainesville, Florida
    • ,
  • Raman M. Patel

      Affiliations

    • High Desert Gastroenterology, Inc, Lancaster, California
    • ,
  • Keith A. Friedenberg

      Affiliations

    • Great Lakes Gastroenterology, Mentor, Ohio
    • ,
  • Preston Dunnmon

      Affiliations

    • Procter & Gamble Pharmaceuticals, Inc, Mason, Ohio
    • ,
  • David Ramsey

      Affiliations

    • Procter & Gamble Pharmaceuticals, Inc, Mason, Ohio
    • ,
  • Sunanda Kane

      Affiliations

    • Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota

Received 14 October 2009 ,Accepted 28 December 2009.

References 

  1. Sandborn WJ, Hanauer SB. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther. 2003;17:29–42
  2. Sandborn WJ. Oral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations?. J Clin Gastroenterol. 2008;42:338–344
  3. Svartz N. Salazopyrin, a new sulfanilamide preparation. Acta Med Scand. 1942;110:577–598
  4. Das KM, Eastwood MA, McManus JP, et al. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med. 1973;289:491–495
  5. Sandberg-Gertzen H, Jarnerot G, Kraaz W. Azodisal sodium in the treatment of ulcerative colitis (A study of tolerance and relapse-prevention properties). Gastroenterology. 1986;90:1024–1030
  6. Ireland A, Mason CH, Jewell DP. Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. Gut. 1988;29:835–837
  7. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis (A randomized study). N Engl J Med. 1987;317:1625–1629
  8. Sninsky CA, Cort DH, Shanahan F, et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis (A multicenter study). Ann Intern Med. 1991;115:350–355
  9. The Mesalamine Study Group. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis (A randomized, placebo-controlled trial). Ann Intern Med. 1996;124:204–211
  10. Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial (Pentasa Study Group). Am J Gastroenterol. 1993;88:1188–1197
  11. Green JR, Lobo AJ, Holdsworth CD, et al. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis (The Abacus Investigator Group). Gastroenterology. 1998;114:15–22
  12. Levine DS, Riff DS, Pruitt R, et al. A randomized, double-blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol. 2002;97:1398–1407
  13. Myers B, Evans DN, Rhodes J, et al. Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut. 1987;28:196–200
  14. Dew MJ, Hughes PJ, Lee MG, et al. An oral preparation to release drugs in the human colon. Br J Clin Pharmacol. 1982;14:405–408
  15. Rasmussen SN, Bondesen S, Hvidberg EF, et al. 5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans. Gastroenterology. 1982;83:1062–1070
  16. D'Haens G, Hommes D, Engels L, et al. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study. Aliment Pharmacol Ther. 2006;24:1087–1097
  17. Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily high concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. 2007;132:66–75
  18. Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2007;5:95–102
  19. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Randomized trial of once- or twice-daily MMX™ mesalazine for maintenance of remission in ulcerative colitis. Gut. 2008;57:893–902
  20. Brunner M, Greinwald R, Kletter K, et al. Gastrointestinal transit and release of 5-aminosalicylic acid from 153Sm-labelled mesalazine pellets vs. tablets in male healthy volunteers. Aliment Pharmacol Ther. 2003;17:1163–1169
  21. Kruis W, Kiudelis G, Racz I, et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut. 2009;58:233–240
  22. Kruis W, Jonaitis L, Pokrotnieks J, et al. Once daily 3 g mesalamine is the optimal dose for maintaining clinical remission in ulcerative colitis: a double-blind, double-dummy, randomized, controlled, dose-ranging study. Gastroenterology. 2008;134(Suppl 1):A489
  23. Prescribing information for Apriso (extended release mesalamine). Morrisville, NC: Salix Pharmaceuticals, Inc; 2009;
  24. Gandia P, Idier I, Houin G. Is once-daily mesalazine equivalent to the currently used twice-daily regimen? (A study performed in 30 healthy volunteers). J Clin Pharmacol. 2007;47:334–342
  25. Dignass AU, Bokemeyer B, Adamek H, et al. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7:762–769
  26. Hussain FN, Ajjan RA, Kapur K, et al. Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. Aliment Pharmacol Ther. 2001;15:53–62
  27. Sandborn WJ, Balan G, Kuzmak B, et al. Comparable pharmacokinetics (PK) of two delayed release formulations of oral mesalamine. Am J Gastroenterol. 2007;102:S465
  28. Kane S, Huo D, Magnanti K. A pilot feasibility study of once daily dosing versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol. 2003;1:170–173
  29. Kane S, Holderman W, Jacques P, et al. Once daily versus conventional dosing of pH-dependent mesalamine long-term to maintain quiescent ulcerative colitis: preliminary results from a randomized trial. Patient Prefer Adherence. 2008;2:253–258
  30. Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut. 1998;43:29–32
  31. Higgins PDR, Schwartz M, Mapili J, et al. Patient defined dichotomous end points for remission and clinical improvement in ulcerative colitis. Gut. 2005;54:782–788
  32. Horne R, Weinman J. Self-regulation and self-management in asthma: exploring the role of illness perceptions and treatment beliefs in explaining non-adherence to preventer medication. Psychol Health. 2002;17:17–32
  33. Miner P, Hanauer S, Robinson M, et al. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis (Pentasa UC Maintenance Study Group). Dig Dis Sci. 1995;40:296–304
  34. Higgins PD, Schwartz M, Mapili J, et al. Is endoscopy necessary for the measurement of disease activity in ulcerative colitis?. Am J Gastroenterol. 2005;100:355–361
  35. Turner D, Seow CH, Greenberg GR, et al. A systematic prospective comparison of non-invasive disease activity indices in ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7:1081–1088
  36. Kane S, Huo D, Aikens J, et al. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med. 2003;114:39–43
  37. Kane SV, Accortt NA, Magowan S, et al. Predictors of persistence with 5-aminosalicylic acid therapy for ulcerative colitis. Aliment Pharmacol Ther. 2009;29:855–862

 This article has an accompanying continuing medical education activity on page e11. Learning Objective: Upon completion of reading this article, successful learners will become familiar with the comparative efficacy of once-daily dosing of delayed-release mesalamine as compared with divided dosing in patients with ulcerative colitis.

 Conflicts of interest These authors disclose the following: William Sandborn has served as a consultant for and received research funding from Procter & Gamble Pharmaceuticals, Inc, and Shire Pharmaceuticals, and has served as a consultant for Salix Pharmaceuticals, Inc; Joshua Korzenik has served as a consultant for Procter & Gamble Pharmaceuticals, Shire, CytokinePharma, Eurand, Zyogenetics, and received research funding from Procter & Gamble Pharmaceuticals; Bret Lashner has served on the Advisory Board/Speakers Bureau for Procter & Gamble Pharmaceuticals, Salix, Shire, UCB, Abbott, and Prometheus; Jonathan Leighton has served as a consultant for Procter & Gamble Pharmaceuticals and received research funding from Procter & Gamble Pharmaceuticals, Abbott, Bristol Myers Squibb, Otsuka, and Centocor; Uma Mahadevan has served as a consultant for Procter & Gamble Pharmaceuticals and Shire; James F. Marion has served as a consultant for Procter & Gamble Pharmaceuticals and has served on the Speakers Bureau for Procter & Gamble Pharmaceuticals, Shire, and UCB; Michael Safdi has received research funding from Forest Research Institute, Conatus, Shire, Tibotec, Millennium, Cosmo, Abbott, Centocor, Pfizer, Elan, Procter & Gamble Pharmaceuticals, Salix Pharmaceuticals, Biolex, Gilead, Roche, Vertex, Celltech, Eisai, BMS, and Lexicon, has served as a consultant for Procter & Gamble Pharmaceuticals, and has served on the Speakers Bureau for Procter & Gamble Pharmaceuticals, Shire, and Centocor; Charles A. Sninsky has served on Advisory Boards and Speakers Bureau for Procter & Gamble Pharmaceuticals, Shire, Centocor, Abbott, UCB, and Prometheus; Keith A. Friedenberg owns shares of Procter & Gamble stock; Preston Dunnmon and David Ramsey are employees of Procter & Gamble Pharmaceuticals; and Sunanda Kane has served as a consultant for and received research funding from Procter & Gamble Pharmaceuticals and Shire. The remaining authors disclose no conflicts: Raman M. Patel.

 Funding This study was funded by Procter & Gamble Pharmaceuticals, Inc, Mason, Ohio. ClinicalTrials.gov Identifier NCT00505778.

 View this article's video abstract at www.gastrojournal.org.

PII: S0016-5085(10)00006-5

doi: 10.1053/j.gastro.2009.12.054

Gastroenterology
Volume 138, Issue 4 , Pages 1286-1296.e3 , April 2010

Article Tools

* Image Usage & Resolution